No profile data available.
SAB Biotherapeutics, Inc. (SABS) is a healthcare company in the antiviral pharmaceuticals industry, based in Miami Beach, United States, with about 86 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of $13.27 million. Its market capitalization was $271.14 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
SAB Biotherapeutics reported $0 in revenue for fiscal year 2025.
$271.14 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Atea Pharmaceuticals, Inc. (AVIR), Arcturus Therapeutics Holdings Inc. (ARCT), Agenus Inc. (AGEN), InflaRx N.v. (IFRX).